Ethambutol - PharmaKB

Ethambutol

Ethambutol, Myambutol (ethambutol) is a small molecule pharmaceutical. Ethambutol was first approved as Myambutol on 1982-01-01. It is used to treat mycobacterium infections, nontuberculous mycobacterium infections, and tuberculosis in the USA.

Download report

Favorite

Searched

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239

Trade Name

FDA

EMA

Ethambutol, Myambutol (discontinued: Ethambutol, Myambutol)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Ethambutol hydrochloride

Tradename	Company	Number	Date	Products
MYAMBUTOL	STI Pharma	N-016320 RX	1982-01-01	2 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
ethambutol	ANDA	2009-11-12
ethambutol hydrochloride	ANDA	2025-07-15
myambutol	New Drug Application	2012-01-05

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
tuberculosis	EFO_0000774	D014376	A15-A19
nontuberculous mycobacterium infections	EFO_0007461	D009165	A31.9
mycobacterium infections	—	D009164	A31.9

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J04: Antimycobacterials

— J04A: Drugs for treatment of tuberculosis

— J04AK: Other drugs for treatment of tuberculosis in atc

— J04AK02: Ethambutol

— J04AM: Combinations of drugs for treatment of tuberculosis

— J04AM03: Ethambutol and isoniazid

— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid

— J04AM07: Rifampicin, ethambutol and isoniazid

HCPCS

No data

Clinical

Clinical Trials

181 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Tuberculosis	D014376	EFO_0000774	A15-A19	12	52	29	12	18	111
Pulmonary tuberculosis	D014397	EFO_1000049	A15	5	39	23	4	8	70
Hiv infections	D015658	EFO_0000764	B20	1	10	13	3	5	30
Mycobacterium infections	D009164	—	A31.9	—	10	11	1	1	20
Mycobacterium avium-intracellulare infection	D015270	EFO_0007386	—	—	8	8	2	1	17
Multidrug-resistant tuberculosis	D018088	EFO_0007381	—	—	7	6	3	3	17
Lung diseases	D008171	EFO_0003818	J98.4	1	4	4	4	—	11
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	—	2	7	1	2	11
Nontuberculous mycobacterium infections	D009165	EFO_0007461	A31.9	—	1	4	1	—	5
Mycobacterium avium complex	D015269	—	—	—	2	2	1	—	4

Show 4 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	—	5	9	—	1	15
Communicable diseases	D003141	—	—	—	4	8	—	1	13
Meningeal tuberculosis	D014390	—	A17.0	1	8	2	—	—	9
Hiv	D006678	—	O98.7	—	2	3	—	—	5
Meningitis	D008581	EFO_0000584	G03	—	2	1	—	—	3
Uveitis	D014605	EFO_1001231	H20.9	—	1	1	—	1	3
Aids-related opportunistic infections	D017088	—	—	—	—	1	—	2	3
Latent tuberculosis	D055985	—	Z22.7	1	1	1	—	1	3
Bacteremia	D016470	EFO_0003033	R78.81	—	1	1	—	—	2
Immunologic deficiency syndromes	D007153	—	D84.9	—	—	2	—	—	2

Show 10 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Sarcoidosis	D012507	EFO_0000690	D80-D89	2	2	—	—	—	3
Pulmonary sarcoidosis	D017565	DOID_13406	D86.0	1	1	—	—	—	2
Hypersensitivity	D006967	EFO_0003785	T78.40	—	2	—	—	—	2
Gram-positive bacterial infections	D016908	—	—	1	1	—	—	—	1
Pharmacokinetics	D010599	—	—	—	1	—	—	—	1
Pharmacological phenomena	D000069437	—	—	—	1	—	—	—	1
Central nervous system diseases	D002493	—	G96.9	—	1	—	—	—	1
Meningoencephalitis	D008590	EFO_0007364	A69.22	—	1	—	—	—	1
Central nervous system tuberculosis	D020306	—	—	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	2	—	—	—	—	2
Chronic obstructive pulmonary disease	D029424	EFO_0000341	J44.9	1	—	—	—	—	1
Obstructive lung diseases	D008173	—	—	1	—	—	—	—	1
Chemical and drug induced liver injury	D056486	EFO_0004228	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Fibrosis	D005355	—	—	—	—	—	—	1	1
Cystic fibrosis	D003550	EFO_0000390	E84	—	—	—	—	1	1
Liver diseases	D008107	EFO_0001421	K70-K77	—	—	—	—	1	1
Body weight	D001835	EFO_0004338	—	—	—	—	—	1	1
Wasting syndrome	D019282	—	—	—	—	—	—	1	1
Body weight changes	D001836	—	—	—	—	—	—	1	1
Motor activity	D009043	EFO_0003940	—	—	—	—	—	1	1
Stomach neoplasms	D013274	EFO_0003897	C16	—	—	—	—	1	1
Malnutrition	D044342	EFO_0008572	E40-E46	—	—	—	—	1	1
Breast feeding	D001942	—	—	—	—	—	—	1	1

Show 2 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Ethambutol
INN	ethambutol
Description	Ethambutol is an ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone. It has a role as an antitubercular agent, an environmental contaminant and a xenobiotic. It is a member of ethanolamines and an ethylenediamine derivative.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC[C@@H](CO)NCCN[C@@H](CC)CO